Literature DB >> 35064002

Mechanisms and Consequences of Cerebellar Purkinje Cell Disinhibition in a Mouse Model of Duchenne Muscular Dystrophy.

Wan-Chen Wu1, Samual P Bradley2, Jason M Christie2, Jason R Pugh3,4.   

Abstract

Duchenne muscular dystrophy (DMD), the most common form of childhood muscular dystrophy, is caused by mutations in the dystrophin gene. In addition to debilitating muscle degeneration, patients display a range of cognitive deficits thought to result from the loss of dystrophin normally expressed in the brain. While the function of dystrophin in muscle tissue is well characterized, its role in the brain is still poorly understood. The highest expression of dystrophin in the mouse brain is in cerebellar Purkinje cells (PCs), where it colocalizes with GABAA receptor clusters. Using ex vivo electrophysiological recordings from connected molecular layer interneuron (MLI)-PC pairs, we investigated changes in inhibitory synaptic transmission caused by dystrophin deficiency. In male mdx mice (which lack long-form dystrophin), we found that responses at MLI-PC pairs were reduced by ∼60% because of both decreased quantal response amplitude and a reduced number of functional vesicle release sites. Using electron microscopy, we found significantly fewer and smaller anatomically defined inhibitory synapses contacting the soma of PCs in mdx mice, suggesting that dystrophin may play a critical role in synapse formation and/or maintenance. Functionally, we found reduced MLI-evoked pauses in PC firing in acute slices. In vivo recordings from awake mdx mice showed increased sensory-evoked simple spike firing in positively modulating PCs, consistent with reduced feedforward inhibition, but no change in negatively modulating PCs. These data suggest that dystrophin deficiency in PCs disrupts inhibitory signaling in the cerebellar circuit and PC firing patterns, potentially contributing to cognitive and motor deficits observed in mdx mice and DMD patients.SIGNIFICANCE STATEMENT Duchenne muscular dystrophy (DMD) is primarily characterized by progressive muscle weakening caused by genetic mutations in the gene for dystrophin. Dystrophin is also normally expressed in the CNS, and DMD patients experience a range of nonprogressive cognitive deficits. The pathophysiology of CNS neurons resulting from loss of dystrophin and the function of dystrophin in neurons are still poorly understood. Using cerebellar PCs as a model, we found that the loss of dystrophin specifically disrupts the number and strength of inhibitory synaptic connections, suggesting that dystrophin participates in formation and/or maintenance of these synapses. This work provides insight into the function of dystrophin in the CNS and establishes neuronal and synaptic dysfunction, which may underlie cognitive deficits in DMD.
Copyright © 2022 the authors.

Entities:  

Keywords:  DMD; Purkinje; dystrophin; inhibition; mdx; synapse

Mesh:

Substances:

Year:  2022        PMID: 35064002      PMCID: PMC8916753          DOI: 10.1523/JNEUROSCI.1256-21.2022

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  52 in total

1.  Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice).

Authors:  I Knuesel; M Mastrocola; R A Zuellig; B Bornhauser; M C Schaub; J M Fritschy
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

2.  A quantal analysis of the synaptic depression underlying habituation of the gill-withdrawal reflex in Aplysia.

Authors:  V F Castellucci; E R Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

3.  A quantitative study of end-plate potentials in isolated human muscle.

Authors:  D Elmqvist; D M Quastel
Journal:  J Physiol       Date:  1965-06       Impact factor: 5.182

4.  Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis.

Authors:  Sue M Cotton; Nicholas J Voudouris; Kenneth M Greenwood
Journal:  Dev Med Child Neurol       Date:  2005-04       Impact factor: 5.449

5.  Analysis of verbal disability in Duchenne muscular dystrophy.

Authors:  N J Karagan; L C Richman; J P Sorensen
Journal:  J Nerv Ment Dis       Date:  1980-07       Impact factor: 2.254

6.  Glutamate spillover suppresses inhibition by activating presynaptic mGluRs.

Authors:  S J Mitchell; R A Silver
Journal:  Nature       Date:  2000-03-30       Impact factor: 49.962

7.  Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations.

Authors:  Valeria Ricotti; William P L Mandy; Mariacristina Scoto; Marika Pane; Nicolas Deconinck; Sonia Messina; Eugenio Mercuri; David H Skuse; Francesco Muntoni
Journal:  Dev Med Child Neurol       Date:  2015-09-14       Impact factor: 5.449

8.  Calcium, synaptic plasticity and intrinsic homeostasis in purkinje neuron models.

Authors:  Pablo Achard; Erik De Schutter
Journal:  Front Comput Neurosci       Date:  2008-12-19       Impact factor: 2.380

9.  Evaluation of narrative abilities in patients suffering from Duchenne Muscular Dystrophy.

Authors:  A Marini; M L Lorusso; M G D'Angelo; F Civati; A C Turconi; F Fabbro; N Bresolin
Journal:  Brain Lang       Date:  2007-04-10       Impact factor: 2.381

10.  Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.

Authors:  Nathalie Doorenweerd; Ahmed Mahfouz; Maaike van Putten; Rajaram Kaliyaperumal; Peter A C T' Hoen; Jos G M Hendriksen; Annemieke M Aartsma-Rus; Jan J G M Verschuuren; Erik H Niks; Marcel J T Reinders; Hermien E Kan; Boudewijn P F Lelieveldt
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

View more
  1 in total

1.  Altered Synaptic Transmission and Excitability of Cerebellar Nuclear Neurons in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Tabita Kreko-Pierce; Jason R Pugh
Journal:  Front Cell Neurosci       Date:  2022-07-05       Impact factor: 6.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.